173 related articles for article (PubMed ID: 12576246)
21. Mifepristone for the treatment of uterine leiomyomas: methodological issues and clinical implications.
Erenbourg A; Piccoli M; Ronfani L; Tamburlini G
Obstet Gynecol; 2009 Mar; 113(3):741. PubMed ID: 19300345
[No Abstract] [Full Text] [Related]
22. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect.
Murphy AA; Morales AJ; Kettel LM; Yen SS
Fertil Steril; 1995 Jul; 64(1):187-90. PubMed ID: 7789557
[TBL] [Abstract][Full Text] [Related]
23. Re: Low-dose mifepristone: Effects on the endometrium. Aust N Z J Obstet Gynaecol 2009; 49: 77-83.
Fraser IS
Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):342. PubMed ID: 19566579
[No Abstract] [Full Text] [Related]
24. [Medical treatment of symptomatic uterine leiomyomata in premenopausal woman].
Koskas M; Derrien J
Presse Med; 2013; 42(7-8):1122-6. PubMed ID: 23602354
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of Xuefu Zhuyu Decoction combined with Mifepristone in the treatment of uterine leiomyoma: A systematic review and meta-analysis.
Shi S; Ye Q; Yu C; Peng F
J Ethnopharmacol; 2021 Dec; 281():114551. PubMed ID: 34428523
[TBL] [Abstract][Full Text] [Related]
26. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486).
Kettel LM; Murphy AA; Morales AJ; Yen SS
Am J Obstet Gynecol; 1998 Jun; 178(6):1151-6. PubMed ID: 9662295
[TBL] [Abstract][Full Text] [Related]
27. [Role of medical treatment for symptomatic leiomyoma management in premenopausal women].
Koskas M; Chabbert-Buffet N; Douvier S; Huchon C; Paganelli E; Derrien J
J Gynecol Obstet Biol Reprod (Paris); 2011 Dec; 40(8):858-74. PubMed ID: 22071015
[TBL] [Abstract][Full Text] [Related]
28. Long-term use of ultra-low-dose mifepristone for uterine leiomyoma control and safety discussion: A case report.
Zhou G; Li Q
Medicine (Baltimore); 2022 Dec; 101(52):e32413. PubMed ID: 36595976
[TBL] [Abstract][Full Text] [Related]
29. Mifepristone: clinical application in general gynecology.
Morales AJ; Kettel LM; Murphy AA
Clin Obstet Gynecol; 1996 Jun; 39(2):451-60. PubMed ID: 8734009
[TBL] [Abstract][Full Text] [Related]
30. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma.
Koivisto-Korander R; Leminen A; Heikinheimo O
Obstet Gynecol; 2007 Feb; 109(2 Pt2):512-4. PubMed ID: 17267877
[TBL] [Abstract][Full Text] [Related]
31. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
32. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.
Watanabe Y; Nakamura G; Matsuguchi H; Nozaki M; Sano M; Nakano H
Fertil Steril; 1992 Jul; 58(1):66-71. PubMed ID: 1624025
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
[TBL] [Abstract][Full Text] [Related]
35. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
[TBL] [Abstract][Full Text] [Related]
36. [Effects of mifepristone on gene expression of epidermal growth factor in human uterine leiomyoma].
Yang Y; Zheng S; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 1998 Jan; 33(1):38-9. PubMed ID: 10682457
[TBL] [Abstract][Full Text] [Related]
37. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri.
Mukherjee S; Chakraborty S
Niger Med J; 2011 Jul; 52(3):150-2. PubMed ID: 22083454
[TBL] [Abstract][Full Text] [Related]
38. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial.
Levens ED; Potlog-Nahari C; Armstrong AY; Wesley R; Premkumar A; Blithe DL; Blocker W; Nieman LK
Obstet Gynecol; 2008 May; 111(5):1129-36. PubMed ID: 18448745
[TBL] [Abstract][Full Text] [Related]
39. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial.
Fiscella K; Eisinger S
Obstet Gynecol; 2008 Sep; 112(3):707; author reply 707-8. PubMed ID: 18757682
[No Abstract] [Full Text] [Related]
40. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
